Patents by Inventor Mohammad Heidaran

Mohammad Heidaran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10590381
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Publication number: 20190376027
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 12, 2019
    Applicant: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Publication number: 20180237744
    Abstract: The present invention provides methods for culturing, expanding and differentiating stem cells, particularly human embryonic stem cells. The methods comprise culturing the stem cells for a period of time on a collagen biofabric, particularly a collagen biofabric derived from the amniotic membrane, chorion, or both, from mammalian placenta.
    Type: Application
    Filed: September 27, 2017
    Publication date: August 23, 2018
    Applicant: CELULARITY INC.
    Inventor: Mohammad Heidaran
  • Publication number: 20170327788
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 9725694
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: August 8, 2017
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 9598669
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: March 21, 2017
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Publication number: 20160298084
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Application
    Filed: June 22, 2016
    Publication date: October 13, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Andrew Zeitlin, Colleen Suzanne Dulaney
  • Patent number: 8455250
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: June 4, 2013
    Assignee: Anthrogenesis Corporation
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Qian Ye, Andrew Zeitlin, Colleen Suzanne Delaney
  • Publication number: 20120121550
    Abstract: The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.
    Type: Application
    Filed: November 9, 2011
    Publication date: May 17, 2012
    Inventor: Mohammad HEIDARAN
  • Patent number: 8071376
    Abstract: The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: December 6, 2011
    Assignee: Anthrogenesis Corporation
    Inventor: Mohammad Heidaran
  • Publication number: 20100291679
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Application
    Filed: July 29, 2010
    Publication date: November 18, 2010
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 7790458
    Abstract: The invention provides populations of expanded CD34-expressing cells and methods of use. Particular embodiments provide for defined culture media useful for growing these cells, and grafts comprising these cells. The invention finds use in methods for reconstituting, repairing, and regenerating tissue damage.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: September 7, 2010
    Assignee: Becton, Dickinson and Company
    Inventors: Ruiling Xu, Andrea Liebmann-Vinson, Keith DeLuca, Mohammad Heidaran
  • Patent number: 7700090
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: April 20, 2010
    Assignee: Anthrogenesis Corporation
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Qian Ye, Andrew Zeitlin, Colleen Suzanne Dulaney
  • Publication number: 20080175824
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 24, 2008
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Qian Ye, Andrew Zeitlin, Colleen Suzanne Dulaney
  • Patent number: 7344884
    Abstract: The present invention provides specific peptides identified as having cell adhesion, growth, expression or secretion-enhancing activities. Many of the peptides of the invention may be produced in large quantity by such means as chemical synthesis or recombinant DNA methodology. They may be non-specifically adsorbed, or chemically attached to a surface or, alternatively, formulated in a culture medium to produce the desired effect on cultured cells.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: March 18, 2008
    Assignee: Becton, Dickinson and Company
    Inventors: Robert L. Campbell, Mohammad Heidaran, Catherine A. Spargo, Jamie H. Wilkins, Perry D. Haaland
  • Publication number: 20080044848
    Abstract: The present invention provides methods for culturing, expanding and differentiating stem cells, particularly human embryonic stem cells. The methods comprise culturing the stem cells for a period of time on a collagen biofabric, particularly a collagen biofabric derived from the amniotic membrane, chorion, or both, from mammalian placenta.
    Type: Application
    Filed: June 8, 2007
    Publication date: February 21, 2008
    Inventor: Mohammad Heidaran
  • Publication number: 20070292399
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Application
    Filed: December 28, 2006
    Publication date: December 20, 2007
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Qian Ye, Andrew Zeitlin, Colleen Dulaney
  • Publication number: 20070292910
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Application
    Filed: December 28, 2006
    Publication date: December 20, 2007
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Qian Ye, Andrew Zeitlin, Colleen Dulaney
  • Publication number: 20070134210
    Abstract: The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.
    Type: Application
    Filed: October 13, 2006
    Publication date: June 14, 2007
    Inventor: Mohammad Heidaran
  • Publication number: 20070077651
    Abstract: The present invention relates to cell adhesion promoting (“CAP”) peptide combinations that promote cell attachment or cell adhesion to culture surfaces that are otherwise cell adhesion resistant “CAR”. The invention provides combination of peptides that, when covalently coupled to a CAR layer such as hyaluronic acid that has been created on a polystyrene surface, promote cell attachment, growth differentiation, and execution of other desired cellular functions in culture.
    Type: Application
    Filed: November 27, 2006
    Publication date: April 5, 2007
    Applicant: Becton, Dickinson and Company
    Inventors: Richard Guarino, Bryce Chaney, Andrea Liebmann-Vinson, Mohammad Heidaran